Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status should be determined for all patients. To optimize treatment, clinicians must not only have current knowledge of current biomarker testing and treatment selection, but also the operational frameworks to effectively translate this latest evidence into practice. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensure your patients are benefitting from the latest advancements in care.
- Provider:University of Chicago School of Medicine
- Activity Link: https://cme.uchicago.edu/node/57277
- Start Date: 2024-06-28 05:00:00
- End Date: 2024-06-28 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Merck and Astellas - Amount: 20000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all